nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—SLC6A3—Gilles de la Tourette syndrome	0.915	1	CbGaD
Citalopram—Escitalopram—SLC6A3—Gilles de la Tourette syndrome	0.00874	1	CrCbGaD
Citalopram—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00669	0.196	CbGeAlD
Citalopram—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00153	0.0366	CbGpPWpGaD
Citalopram—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00128	0.0374	CbGeAlD
Citalopram—HTR2C—midbrain—Gilles de la Tourette syndrome	0.00123	0.0361	CbGeAlD
Citalopram—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00123	0.0293	CbGpPWpGaD
Citalopram—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00118	0.0281	CbGpPWpGaD
Citalopram—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00117	0.0342	CbGeAlD
Citalopram—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00106	0.0254	CbGpPWpGaD
Citalopram—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00105	0.0307	CbGeAlD
Citalopram—HTR2C—nervous system—Gilles de la Tourette syndrome	0.00101	0.0297	CbGeAlD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00101	0.0242	CbGpPWpGaD
Citalopram—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00101	0.0241	CbGpPWpGaD
Citalopram—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00101	0.0296	CbGeAlD
Citalopram—HTR2C—central nervous system—Gilles de la Tourette syndrome	0.000977	0.0286	CbGeAlD
Citalopram—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.000962	0.0282	CbGeAlD
Citalopram—CHRM1—nervous system—Gilles de la Tourette syndrome	0.000958	0.028	CbGeAlD
Citalopram—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.000926	0.0271	CbGeAlD
Citalopram—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.000923	0.027	CbGeAlD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000878	0.021	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000875	0.0209	CbGpPWpGaD
Citalopram—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000864	0.0206	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000862	0.0206	CbGpPWpGaD
Citalopram—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.000847	0.0248	CbGeAlD
Citalopram—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000839	0.02	CbGpPWpGaD
Citalopram—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.000817	0.0195	CbGpPWpGaD
Citalopram—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000815	0.0239	CbGeAlD
Citalopram—SLC6A3—brain—Gilles de la Tourette syndrome	0.000802	0.0235	CbGeAlD
Citalopram—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.000787	0.023	CbGeAlD
Citalopram—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000782	0.0187	CbGpPWpGaD
Citalopram—HTR2C—brain—Gilles de la Tourette syndrome	0.000776	0.0227	CbGeAlD
Citalopram—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.000758	0.0222	CbGeAlD
Citalopram—HRH1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000749	0.0179	CbGpPWpGaD
Citalopram—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000746	0.0178	CbGpPWpGaD
Citalopram—SLC6A4—brain—Gilles de la Tourette syndrome	0.000735	0.0215	CbGeAlD
Citalopram—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000735	0.0175	CbGpPWpGaD
Citalopram—CHRM1—brain—Gilles de la Tourette syndrome	0.000732	0.0214	CbGeAlD
Citalopram—HRH1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000727	0.0174	CbGpPWpGaD
Citalopram—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000726	0.0173	CbGpPWpGaD
Citalopram—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000725	0.0173	CbGpPWpGaD
Citalopram—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000713	0.017	CbGpPWpGaD
Citalopram—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000705	0.0168	CbGpPWpGaD
Citalopram—HRH1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000677	0.0162	CbGpPWpGaD
Citalopram—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000675	0.0161	CbGpPWpGaD
Citalopram—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000665	0.0159	CbGpPWpGaD
Citalopram—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000657	0.0157	CbGpPWpGaD
Citalopram—SLC6A2—brain—Gilles de la Tourette syndrome	0.000647	0.0189	CbGeAlD
Citalopram—HRH1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00063	0.015	CbGpPWpGaD
Citalopram—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000627	0.015	CbGpPWpGaD
Citalopram—CYP2B6—nervous system—Gilles de la Tourette syndrome	0.000624	0.0183	CbGeAlD
Citalopram—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000618	0.0147	CbGpPWpGaD
Citalopram—HRH1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000611	0.0146	CbGpPWpGaD
Citalopram—HRH1—nervous system—Gilles de la Tourette syndrome	0.000609	0.0178	CbGeAlD
Citalopram—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000609	0.0145	CbGpPWpGaD
Citalopram—ADRA1A—brain—Gilles de la Tourette syndrome	0.000602	0.0176	CbGeAlD
Citalopram—CYP2B6—central nervous system—Gilles de la Tourette syndrome	0.000601	0.0176	CbGeAlD
Citalopram—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0006	0.0143	CbGpPWpGaD
Citalopram—HRH1—central nervous system—Gilles de la Tourette syndrome	0.000587	0.0172	CbGeAlD
Citalopram—CYP2E1—nervous system—Gilles de la Tourette syndrome	0.000586	0.0171	CbGeAlD
Citalopram—HRH1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000569	0.0136	CbGpPWpGaD
Citalopram—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000567	0.0135	CbGpPWpGaD
Citalopram—CYP2E1—central nervous system—Gilles de la Tourette syndrome	0.000564	0.0165	CbGeAlD
Citalopram—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000559	0.0133	CbGpPWpGaD
Citalopram—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000547	0.0131	CbGpPWpGaD
Citalopram—CYP2B6—brain—Gilles de la Tourette syndrome	0.000477	0.014	CbGeAlD
Citalopram—HRH1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000474	0.0113	CbGpPWpGaD
Citalopram—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000473	0.0113	CbGpPWpGaD
Citalopram—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.000471	0.0138	CbGeAlD
Citalopram—HRH1—brain—Gilles de la Tourette syndrome	0.000466	0.0136	CbGeAlD
Citalopram—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000465	0.0111	CbGpPWpGaD
Citalopram—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000464	0.0136	CbGeAlD
Citalopram—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00046	0.011	CbGpPWpGaD
Citalopram—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.000454	0.0133	CbGeAlD
Citalopram—CYP2E1—brain—Gilles de la Tourette syndrome	0.000448	0.0131	CbGeAlD
Citalopram—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000446	0.0131	CbGeAlD
Citalopram—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000416	0.00994	CbGpPWpGaD
Citalopram—ABCB1—midbrain—Gilles de la Tourette syndrome	0.000406	0.0119	CbGeAlD
Citalopram—HRH1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000399	0.00952	CbGpPWpGaD
Citalopram—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000397	0.00949	CbGpPWpGaD
Citalopram—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000391	0.00934	CbGpPWpGaD
Citalopram—CYP2D6—brain—Gilles de la Tourette syndrome	0.000354	0.0104	CbGeAlD
Citalopram—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000349	0.00833	CbGpPWpGaD
Citalopram—ABCB1—nervous system—Gilles de la Tourette syndrome	0.000334	0.00976	CbGeAlD
Citalopram—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.000321	0.0094	CbGeAlD
Citalopram—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.0003	0.00717	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000294	0.00701	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000285	0.00681	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000266	0.00634	CbGpPWpGaD
Citalopram—ABCB1—brain—Gilles de la Tourette syndrome	0.000255	0.00746	CbGeAlD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000228	0.00544	CbGpPWpGaD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000189	0.00452	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000176	0.0042	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000171	0.00408	CbGpPWpGaD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000167	0.00398	CbGpPWpGaD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000162	0.00386	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000159	0.0038	CbGpPWpGaD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000151	0.0036	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000145	0.00345	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000144	0.00344	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000143	0.00341	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000142	0.00338	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00014	0.00335	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00014	0.00334	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000139	0.00331	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000138	0.00329	CbGpPWpGaD
Citalopram—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000137	0.00326	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000131	0.00312	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00013	0.00311	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000129	0.00308	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000128	0.00306	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000124	0.00296	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000123	0.00295	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000122	0.00292	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000122	0.0029	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00012	0.00287	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00012	0.00286	CbGpPWpGaD
Citalopram—HRH1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000118	0.00283	CbGpPWpGaD
Citalopram—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000118	0.00282	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000118	0.00282	CbGpPWpGaD
Citalopram—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000116	0.00277	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000112	0.00267	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000112	0.00266	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00011	0.00262	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000109	0.0026	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000106	0.00253	CbGpPWpGaD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000106	0.00252	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000106	0.00252	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000106	0.00252	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000104	0.00248	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.84e-05	0.00235	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	9.62e-05	0.0023	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.43e-05	0.00225	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.4e-05	0.00224	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.25e-05	0.00221	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.15e-05	0.00218	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.15e-05	0.00218	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.12e-05	0.00218	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.12e-05	0.00218	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.05e-05	0.00216	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	8.98e-05	0.00214	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	8.98e-05	0.00214	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.53e-05	0.00204	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.5e-05	0.00203	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.37e-05	0.002	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	7.84e-05	0.00187	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	7.82e-05	0.00187	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	7.73e-05	0.00184	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	7.7e-05	0.00184	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—HDC—Gilles de la Tourette syndrome	7.57e-05	0.00181	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.89e-05	0.00165	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.15e-05	0.00147	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	5.97e-05	0.00143	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.97e-05	0.00142	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	5.95e-05	0.00142	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	5.86e-05	0.0014	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	5.84e-05	0.00139	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	5.7e-05	0.00136	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.58e-05	0.00133	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.56e-05	0.00133	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.42e-05	0.00129	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	5.37e-05	0.00128	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.33e-05	0.00127	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.31e-05	0.00127	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.23e-05	0.00125	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.17e-05	0.00123	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.16e-05	0.00123	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.08e-05	0.00121	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.05e-05	0.00121	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.84e-05	0.00115	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.82e-05	0.00115	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.82e-05	0.00115	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.8e-05	0.00115	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.75e-05	0.00113	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.73e-05	0.00113	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.7e-05	0.00112	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.68e-05	0.00112	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.61e-05	0.0011	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	4.55e-05	0.00109	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.38e-05	0.00104	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.36e-05	0.00104	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.29e-05	0.00102	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	4.23e-05	0.00101	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.9e-05	0.00093	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.54e-05	0.000844	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	3.51e-05	0.000838	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.38e-05	0.000806	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.36e-05	0.000803	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.31e-05	0.00079	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.3e-05	0.000787	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.2e-05	0.000764	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.06e-05	0.000732	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.06e-05	0.000729	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.01e-05	0.000718	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.98e-05	0.000712	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.86e-05	0.000682	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.85e-05	0.00068	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.8e-05	0.000669	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.77e-05	0.000662	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.77e-05	0.00066	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.72e-05	0.00065	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.59e-05	0.000617	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.58e-05	0.000615	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.54e-05	0.000605	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.09e-05	0.000499	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.81e-05	0.000432	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.8e-05	0.000431	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.78e-05	0.000424	CbGpPWpGaD
